Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-12-05
|
Jakavi®/Jakafi® - INC424 (ruxolitinib) |
polycythaemia vera |
3 |
Novartis (Switzerland) |
Rare diseases |
2015-12-05
|
Jakafi® - INC424 (ruxolitinib) |
myelofibrosis |
3 |
Novartis (Switzerland) |
Cancer - Oncology - Blood diseases - Hematological diseases |
2015-12-05
|
AG-120 - isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor |
advanced hematologic malignancies including elapsed or refractory acute myeloid leukemia (AML), untreated AML and other IDH1-mutated positive hematologic malignancies |
1 |
Agios Pharmaceuticals (USA - MA) |
Cancer - Oncology - Rare diseases |
2015-12-05
|
Gazyva™ (obinutuzumab - GA101) |
chronic lymphocytic leukemia (CLL) |
3 |
Genentech, a member of the Roche Group (USA - Switzerland) |
Cancer - Oncology |
2015-12-05
|
cytotoxic T lymphocytes (CTL) activated against Wilms' Tumor 1 (WT1-CTL) |
relapsed-refractory multiple myeloma |
1 |
Atara Biotherapeutics (USA - CA) Memorial Sloan Kettering Cancer Center (USA - NY) |
Cancer - Oncology |
2015-12-05
|
GMI-1271 |
acute myeloid leukemia (AML) |
1 |
GlycoMimetics (USA - Md) |
Cancer - Oncology |
2015-12-05
|
IMO-8400 - antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9 |
Waldenstrom's macroglobulinemia |
1-2 |
Idera Pharmaceuticals (USA - CA) |
Cancer - Oncology - Rare diseases |
2015-12-04
|
citarinostat (ACY-241) and nivolumab |
non-small cell lung cancer (NSCLC) |
1b |
Acetylon Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2015-12-04
|
BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) |
diffuse large B-cell lymphoma (DLBCL) |
2 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2015-12-04
|
ARC-520 |
hepatitis B |
preclinical |
Arrowhead Research Corporation (USA - CA) |
Infectious diseases |
2015-12-02
|
NW-3509 |
schizophrenia |
2 |
Newron Pharmaceuticals (Italy) |
CNS diseases - Mental diseases |
2015-12-01
|
tumor growth factor kinoid |
|
preclinical |
Neovacs (France) |
Cancer - Oncology |
2015-12-01
|
NI-0501 |
hemophagocytic lymphohistiocytosis (HLH) |
2 |
NovImmune (Switzerland) |
Rare diseases - Immunological diseases |
2015-12-01
|
PledOx™ |
reduction of side effects caused by the chemotherapy FOLFOX in patients treated for metastatic colorectal cancer |
2 |
PledPharma (Sweden) |
Cancer - Oncology |
2015-12-01
|
Ryzodeg® |
type 2 diabetes |
|
Novo Nordisk (Denmark) |
Metabolic diseases |
2015-12-01
|
N91115 (S-nitrosoglutathione reductase inhibitor) with lumacaftor/ivacaftor (Orkambi™) |
cystic fibrosis in patients who have two copies of the F508del mutation |
2 |
Nivalis Therapeutics (USA - CO) |
Rare diseases - Genetic diseases |
2015-12-00
|
pidilizumab (MDV9300) |
relapsed or refractory diffuse large B-cell lymphoma |
2 |
Medivation (USA - CA) now Pfizer (USA - NY) |
Cancer - Oncology |
2015-12-00
|
pidilizumab (MDV9300) |
relapsed or refractory diffuse large B-cell lymphoma |
2 |
Medivation (USA - CA) now Pfizer (USA - NY) |
Cancer - Oncology |
2015-11-30
|
Clevegen® |
|
|
Faron Pharmaceuticals (Finland) |
Cancer - Oncology |
2015-11-30
|
INT-767 |
|
1 |
Intercept Pharmaceuticals (USA - NY) |
|